Antibacterial, antifungal and cytotoxic activity of terrestrial cyanobacterial strains from Serbia

Science in China, Series C: Life Sciences

Volumn 51, Issue 10, 2008, Pages 941-947

  Svircev, Zorica ^a   Cetojevic Simin, Dragana ^b   Simeunovic, Jelica ^a   Karaman, Maja ^a   Stojanovic, Dejan ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b ONCOLOGY INSTITUTE OF VOJVODINA   (Serbia)

Author keywords

Antibacterial; Antifungal; Cyanobacteria; Cytotoxic; Screening

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYANOBACTERIUM; DRUG EFFECT; HUMAN; SERBIA;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CELL LINE; CELL SURVIVAL; CYANOBACTERIA; HUMANS; SERBIA;

ANABAENA; BACTERIA (MICROORGANISMS); CYANOBACTERIA; NOSTOC;

EID: 52649123662     PISSN: 10069305     EISSN: 18622798     Source Type: Journal    
DOI: 10.1007/s11427-008-0115-8     Document Type: Article

References (44)

1. Chapman D J, Gellenbeck K W. An historical perspective of algal biotechnology. In: Cresswell R C, Rees T A V, Shah N, eds. Algal and Cyanobacterial Biotechnology UK. Harlow: Longman Scientific and Technical, 1998. 1-23
2. G. M. L. Patterson L. K. Larsen R. E. Moore 1994 Bioactive natural products from blue-green algae J Appl Phycol 6 151 157
3. R. Frassanito M. Cantonati M. Tardìo 2005 On-line identification of secondary metabolites in freshwater microalgae and cyanobacteria by combined liquid chromatography-photodiode array detection-mass spectrometric techniques J Chromatography 1 33 42
4. T. L. Tan 2007 Bioactive natural products from marine cyanobacteria for drug discovery Phytochemistry 7 954 979
5. W. W. Carmichael 1992 Cyanobacteria secondary metabolities-the cytotoxins J Appl Bacteriol 72 445 459
6. G. A. Codd 2000 Cyanobacterial toxins, the perception of water quality, and the prioritisation of eutrophication control Ecol Eng 16 51 60
7. J. B. Berry M. Gantar R. E. Gawley 2004 Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from freshwater species of Lyngbya isolated from the Florida Everglades Comparat Biochem Physiol (Part C) 139 231 238
8. C. Wiegand S. Pflugmacher 2005 Ecotoxicological effects of selected cyanobacterial secondary metabolites a short review Toxicol Appl Pharmacol 3 201 218
9. A. M. Burja B. B. Banaigs E. Abou-Mansour 2001 Marine cyanobacteria-a prolific source of natural products Tetrahedron 57 9347 9377
10. W. C. Dunlap C. N. Battershill C. H. Liptrot 2007 Biomedicinals from the phytosymbionts of marine invertebrates: A molecular approach Methods 4 358 376
11. B. S. Falch G. M. Koening A. D. Wright 1995 Biological activity of cyanobacteria: Evaluation of extracts and pure compounds Planta Med 61 321 328
12. R.-B. Volk F. H. Furkert 2006 Antialgal, antibacterial and antifungal activity of two metabolites produced and excreted by cyanobacteria during growth Microbiol Res 161 180 186
13. R. Valdor M. Aboal 2007 Effect of living cyanobacteria, cyanobacterial extracts and pure microcystins on growth and ultrastructure of microalgae and bacteria Toxicon 49 769 779
14. I. Schlegel N. T. Doan N. De Chazal 1999 Antibiotic activity of a new cyanobacterial isolates from Australia and Asia against algae and cyanobacteria J Appl Phycol 10 471 479
15. W. P. Frankmölle L. K. Larsen F. R. Caplan 1992 Antifungal cyclic peptides from the terrestrial blue-green alga Anabaena laxa J Antibiot 45 1451 1457
16. S. Loya V. Reshef E. Mizrachi 1998 The inhibition of the reverse transcriptase of HIV-1 by the natural sulfoglycolipids from cyanobacteria: Contribution of different moieties to their potency J Nat Prod 61 891 895
17. O. M. Skulberg 2000 Microalgae as a source of bioactive molecules-experience from cyanophyte research J Appl Microbiol 12 341 348
18. M. M. Wagner D. C. Paul C. Shih 1999 In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines Cancer Chemother Pharmacol 43 115 125
19. J. P. Stevenson M. Gallagher D. Vaughn 1999 Phase I trial of the cryptophycin analogue LY355703 administered as an IV infusion, D1 and D8, repeated every 21 days Proc Am Assoc Cancer Res 40 92
20. C. Sessa K. Weigang-Kohler O. Pagani 2002 Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule Europ J Cancer 38 2388 2396
21. Moore R E, Patterson G M L, Carmichael W W. New pharmaceuticals from cultured blue-green algae. In: Fautin D G, eds. Biomedical Importance of Marine Organisms. Mem Cal Acad Sci, 1988, 13. 143-150
22. H. Leusch R. E. Moore V. J. Paul 2001 Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1 J Nat Prod 64 907 910
23. R. E. Moore 1996 Cyclic peptides and depsipeptides from cyanobacteria: A review J Ind Microbiol 16 134 143
24. C. D. Smith X. Zhang 1996 Mechanism of action of Cryptophycin J Biol Chem 271 6192 6198
25. L. Drew R. L. Fine T. N. Do 2002 The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer Clin Cancer Res 8 3922 3932
26. B. S. Davidson 1995 New dimensions in natural products research: cultured marine microorganisms Curr Opin Biotechnol 6 284 291
27. H. Tokuda H. Nishino H. Shirahashi 1996 Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue Cancer Lett 104 91 95
28. Reisser W. Biotechnological potentials of aeroterrestrial algae. Abstract Book 4th European Workshop. Biotechnology of Microalgae, May 2000 Bergholz-Rehbrücke, Germany, pp49
29. M. Gantar Z. Obreht O. Fojkar 1991 Occurrence and characterization of nitrogen-fixing cyanobacteria in different temperate soils Mikrobiologija (YU) 28 33 44
30. R. Rippka J. Deruelles J. B. Waterbury 1979 Generic assignments, strain histories and properties of pure cultures of cyanobacteria J Gen Microbiol 111 1 61
31. Østensvik O. M. Skulberg B. Underdal 1998 Antibacterial properties of extracts from selected planktonic feshwater cyanobacteria-a comparative study of bacterial bioassays J Appl Microbiol 84 1117 1124
32. P. Skehan R. Storeng D. Scudiero 1990 New colorimetric cytotoxicity assay for anticancer-drug screening J Nat Cancer Inst 13 1107 1112
33. R. Piccardi A. Frosini M. R. Tredici 2000 Bioactivity in free-living and symbiotic cyanobacteria of the genus Nostoc J Appl Phycol 12 543 547
34. I. Tamas Z. Svircev S. G. E. Anderson 2000 Determinative value of a portion of the nif H sequence for the genera Nostoc and Anabaena (Cyanobacteria) Curr Microbiol 41 197 200
35. B. Jaki J. Orjala H.-R. Buergi 1999 Biological screening of cyanobacteria for antimicrobial and molluscicidal activity, brine shrimp lethality, and cytotoxicity Pharm Biol 37 138 143
36. S. Lyck N. Gjolme H. Utkilen 1996 Iron starvation increases toxicity of Microcystis aeruginosa CYA 228/1 (Chroococcales, Cyanophyceae) Phycologia 35 120 124
37. S. Bloor R. R. England 1991 Elucidation and optimisation of the medium constituents controlling antibiotic production by the cyanobacterium Nostoc muscorum Enz Microb Technol 13 76 81
38. A. Kosakowska M. Nedzi J. Pempkowiak 2007 Responses of the toxic cyanobacterium Microcystis aeruginosa to iron and humic substances Plant Phys Biochem 45 365 370
39. G. Burgess E. M. Jordan M. Bregu 1999 Microbial antagonism: a neglected avenue of natural products research J Biotech 70 27 32
40. J. E. Armstrong K. E. Janda B. Alvarado 1991 Cytotoxin production by a marine Lyngbya strain (cyanobacterium) in a large-scale laboratory bioreactor J Appl Phycol 3 277 282
41. E. J. Calabrese L. A. Baldwin 2001 The scientific foundation of hormesis Crit Rev Toxicol 31 349 691
42. E. J. Calabrese L. A. Baldwin 2001 Agonist concentration gradients as a generalizable regulatory implementation strategy Crit Rev Toxicol 31 471 474
43. E. J. Calabrese 2005 Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences Environ Pollut 138 378 411
44. S. Kreitlow S. Mundt U. Lindequist 1999 Cyanobacteria-a potential source of new biologically active substances J Biotech 70 61 63